Education
About Us
Working with TipRanks
Follow Us
Medtide, Inc. Class H (HK:3880)
:3880
3880 Stock Chart & Stats
HK$30.00
--
Market closed
HK$30.00
--
Day’s Range― - ―
52-Week RangeHK$21.50 - HK$41.72
Previous CloseN/A
VolumeN/A
Average Volume (3M)155.10K
Market Cap
HK$3.26B
Enterprise ValueHK$3.17B
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)27.4
Beta0.87
Next Earnings
Mar 30, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.93
Shares Outstanding141,800,000
10 Day Avg. Volume149,470
30 Day Avg. Volume155,096
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)2.23
Revenue Forecast (FY)HK$804.85M
Medtide, Inc. Class H News
3880 FAQ
What was Medtide, Inc. Class H’s price range in the past 12 months?
Medtide, Inc. Class H lowest stock price was HK$21.50 and its highest was HK$41.72 in the past 12 months.
What is Medtide, Inc. Class H’s market cap?
Medtide, Inc. Class H’s market cap is HK$3.26B.
When is Medtide, Inc. Class H’s upcoming earnings report date?
Medtide, Inc. Class H’s upcoming earnings report date is Mar 30, 2026 which is in 12 days.
How were Medtide, Inc. Class H’s earnings last quarter?
Medtide, Inc. Class H released its earnings results on Aug 29, 2025. The company reported HK$0.933 earnings per share for the quarter, missing the consensus estimate of HK$6.427 by -HK$5.494.
Is Medtide, Inc. Class H overvalued?
According to Wall Street analysts Medtide, Inc. Class H’s price is currently Overvalued.
Does Medtide, Inc. Class H pay dividends?
Medtide, Inc. Class H does not currently pay dividends.
What is Medtide, Inc. Class H’s EPS estimate?
Medtide, Inc. Class H’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medtide, Inc. Class H have?
Medtide, Inc. Class H has 141,800,000 shares outstanding.
What happened to Medtide, Inc. Class H’s price movement after its last earnings report?
Medtide, Inc. Class H reported an EPS of HK$0.933 in its last earnings report, missing expectations of HK$6.427. Following the earnings report the stock price went down -4.835%.
Which hedge fund is a major shareholder of Medtide, Inc. Class H?
Currently, no hedge funds are holding shares in HK:3880
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medtide, Inc. Class H Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Fundamentals
Return on Equity
12.26%
Trailing 12-Months
Asset Growth
68.00%
Trailing 12-Months
Company Description
Medtide, Inc. Class H
Medtide Inc., a contract research, development, and manufacturing company, provides early-stage discovery, preclinical research, clinical development, and commercial-stage production services. It offers peptide new chemical entity discovery synthesis, peptide chemistry, manufacturing, and control development and commercial manufacturing services. The company focuses on developing oral and/or injectable glucagon, such as peptide-1 (GLP-1) molecule products. Its research and development technology platform include OmniPeptSynth, PeptiConjuX, PeptiNuclide LinkTech, GreenSynth Innovations, and Impurity Screening. It serves customers in China, the United States, Japan, Europe, South Korea, and Australia. The company was formerly known as Taide Pharmaceutical (Zhejiang) Co., Ltd and changed its name to Medtide Inc. in February 2023. Medtide Inc. was incorporated in 2020 and is headquartered in Hangzhou, China.
Technical Analysis
Genor Biopharma Holdings Limited
―
Jacobio Pharmaceuticals Group Co., Ltd.
―
Viva Biotech Holdings
―
Clover Biopharmaceuticals Ltd.
―
ImmuneOnco Biopharmaceuticals (Shanghai) Inc Class H
―